Piramal Pharma Solutions has announced an investment of $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and antibody-drug conjugate (ADC) therapies.
A ground-breaking ceremony was held on 25 June 2025 to mark the commencement of work on Lexington’s site expansion.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company’s Riverview, Michigan site is expected to be operational by the end of 2025 and will undergo an enhancement that includes adding a commercial scale suite designed specifically for high potency APIs (HPAPIs).
The Riverview facility will also provide payload-linkers, which are crucial for the safety and efficacy of ADC therapies, under the company’s ADCelerate programme.
In Lexington, Kentucky, Piramal Pharma is increasing its fill/finish facility with an additional 24,000ft² of manufacturing space.
The expansion will introduce a new laboratory and advanced machinery such as a new filling line, two large size lyophilisers, a capping machine and an external vial washer.
The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches.
Piramal Global Pharma CEO Peter DeYoung stated: “ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumours.
“As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.”
The expansions come amid surging market growth for sterile injectables due to increased medical needs, regulatory approvals and scientific progress.
ADC therapies are witnessing high interest due to their efficacy and wider acceptance among healthcare regulators. The investment at the Lexington site goes beyond capacity building but also contributes to 40 new permanent positions.
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
